NCT05541341View on ClinicalTrials.gov

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

November 23, 2043

Study Completion Date

November 23, 2043

Conditions
Diffuse Large B-cell LymphomaAcute Lymphoblastic LeukemiaFollicular Lymphoma
Interventions
OTHER

tisagenlecleucel

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Trial Locations (7)

34006-059

RECRUITING

Novartis Investigative Site, Minas Gerais

41253-190

RECRUITING

Novartis Investigative Site, Salvador

81520-060

RECRUITING

Novartis Investigative Site, Curitiba

01323-900

RECRUITING

Novartis Investigative Site, São Paulo

04544-000

RECRUITING

Novartis Investigative Site, São Paulo

01409-902

RECRUITING

Novartis Investigative Site, São Paulo

01509-010

RECRUITING

Novartis Investigative Site, São Paulo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY